Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington’s disease peripheral blood samples

Metabolomics

Volumn 12, Issue 8, 2016, Pages

  Mastrokolias, Anastasios ^a   Pool, Rene ^b,c   Mina, Eleni ^a   Hettne, Kristina M ^a   van Duijn, Erik ^a,d   van der Mast, Roos C ^a   van Ommen, GertJan ^a   ‘t Hoen, Peter A C ^a   Prehn, Cornelia ^e   Adamski, Jerzy ^e,f,g   van Roon Mom, Willeke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Center for Mental Health Care Delfland   (Netherlands)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biomarkers; Disease progression; Gene expression; Integrated analysis; Metabolomics; Neurodegenerative

Indexed keywords

15 LYSO PHOSPHATIDYLCHOLINE; 77 PHOSPHATIDYLCHOLINE; ACYLCARNITINE; AMINO ACID DERIVATIVE; CARNITINE; DICARBOXYLACYLCARNITINE; HEXOSE; HYDROXYLACYLCARNITINE; N HYDROXYACYLOYLSPHINGOSYLPHOSPHOCOLINE; PHOSPHATIDYLCHOLINE; SERINE; SPHINGOMYELIN; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL NEURAL NETWORK; ASYMPTOMATIC DISEASE; BLOOD SAMPLING; BODY MASS; COMPUTER MODEL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE SEVERITY; DISTRESS SYNDROME; DNA TRANSCRIPTION; EARLY DIAGNOSIS; ELECTROSPRAY MASS SPECTROMETRY; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; METABOLOMICS; MUTATION; NEXT GENERATION SEQUENCING; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS;

EID: 84979657059     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-016-1084-8     Document Type: Article

References (88)

1. Abildtrup, M., & Shattock, M. (2013). Cardiac Dysautonomia in Huntington’s disease. Journal of Huntington’s disease, 2(3), 251–261.
2. Acuna, A. I., et al. (2013). A failure in energy metabolism and antioxidant uptake precede symptoms of Huntington’s disease in mice. Nature Communications, 4, 2917.
3. Adibhatla, R. M., & Hatcher, J. F. (2008). Altered lipid metabolism in brain injury and disorders. Sub-Cellular Biochemistry, 49, 241–268.
4. Adibhatla, R. M., Hatcher, J. F., & Dempsey, R. J. (2006). Lipids and lipidomics in brain injury and diseases. The AAPS Journal, 8(2), E314–E321.
5. Andre, R., Carty, L., & Tabrizi, S. J. (2016). Disruption of immune cell function by mutant huntingtin in Huntington’s disease pathogenesis. Current Opinion in Pharmacology, 26, 33–38.
6. Andrich, J., et al. (2004). Hyperhomocysteinaemia in treated patients with Huntington’s disease homocysteine in HD. Movement Disorders, 19(2), 226–228.
7. Bonilla, E., Prasad, A. L., & Arrieta, A. (1988). Huntington’s disease: Studies on brain free amino acids. Life Sciences, 42(11), 1153–1158.
8. Ceglarek, U., Muller, P., Stach, B., Buhrdel, P., Thiery, J., & Kiess, W. (2002). Validation of the phenylalanine/tyrosine ratio determined by tandem mass spectrometry: Sensitive newborn screening for phenylketonuria. Clinical Chemistry and Laboratory Medicine, 40(7), 693–697.
9. Cheverud, J. M. (2001). A simple correction for multiple comparisons in interval mapping genome scans. Heredity (Edinb), 87(Pt 1), 52–58.
10. Cuturic, M., Abramson, R. K., Moran, R. R., Hardin, J. W., Frank, E. M., & Sellers, A. A. (2013). Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington’s disease patients. Neurological Sciences, 34(1), 93–98.
11. Deckel, A. W. (2001). Nitric oxide and nitric oxide synthase in Huntington’s disease. Journal of Neuroscience Research, 64(2), 99–107.
12. Deckel, A. W., et al. (2000). Dietary arginine alters time of symptom onset in Huntington’s disease transgenic mice. Brain Research, 875(1–2), 187–195.
13. Desplats, P. A., et al. (2007). Glycolipid and ganglioside metabolism imbalances in Huntington’s disease. Neurobiology of Disease, 27(3), 265–277.
14. Dharuri, H., et al. (2013). Automated workflow-based exploitation of pathway databases provides new insights into genetic associations of metabolite profiles. BMC Genomics, 14, 865.
15. Diamanti, D., et al. (2013). Whole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model. Biomarker Research, 1(1), 28.
16. Draisma, H. H., et al. (2015). Genome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levels. Nature Communications, 6, 7208.
17. Evers, M. M., et al. (2011). Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS ONE, 6(9), e24308.
18. Fonteh, A. N., et al. (2013). Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer’s disease. Journal of Lipid Research, 54(10), 2884–2897.
19. Gieger, C., et al. (2008). Genetics meets metabolomics: A genome-wide association study of metabolite profiles in human serum. PLoS Genetics, 4(11), e1000282.
20. Growdon, J. (1987). Use of phosphatidylcholine in brain diseases: An overview. In I. Hanin & G. B. Ansell (Eds.), Lecithin (33rd ed., pp. 121–136). New York: Springer.
21. Gruber, B., et al. (2013). Huntington’ disease–imbalance of amino acid levels in plasma of patients and mutation carriers. Annals of Agricultural and Environmental Medicine, 20(4), 779–783.
22. Gulati, S., Liu, Y., Munkacsi, A. B., Wilcox, L., & Sturley, S. L. (2010). Sterols and sphingolipids: Dynamic duo or partners in crime? Progress in Lipid Research, 49(4), 353–365.
23. Hardingham, G. E., & Bading, H. (2010). Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders. Nature Reviews Neuroscience, 11(10), 682–696.
24. Hastings, J., et al. (2013). The ChEBI reference database and ontology for biologically relevant chemistry: Enhancements for 2013. Nucleic Acids Research, 41(Database issue), D456–D463.
25. Heipertz, R., Pilz, H., & Scholz, W. (1977). The fatty acid composition of sphingomyelin from adult human cerebral white matter and changes in childhood, senium and unspecific brain damage. Journal of Neurology, 216(1), 57–65.
26. Higatsberger, M. R., Sperk, G., Bernheimer, H., Shannak, K. S., & Hornykiewicz, O. (1981). Striatal ganglioside levels in the rat following kainic acid lesions: Comparison with Huntington’s disease. Experimental Brain Research, 44(1), 93–96.
27. Hodges, A., et al. (2006). Regional and cellular gene expression changes in human Huntington’s disease brain. Human Molecular Genetics, 15(6), 965–977.
28. Illig, T., et al. (2010). A genome-wide perspective of genetic variation in human metabolism. Nature Genetics, 42(2), 137–141.
29. Jacob, R. A., Jenden, D. J., Allman-Farinelli, M. A., & Swendseid, M. E. (1999). Folate nutriture alters choline status of women and men fed low choline diets. Journal of Nutrition, 129(3), 712–717.
30. Johri, A., Chandra, A., & Beal, M. F. (2013). PGC-1alpha, mitochondrial dysfunction, and Huntington’s disease. Free Radical Biology and Medicine, 62, 37–46.
31. Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010). KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Research, 38(Database issue), D355–D360.
32. Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., & Tanabe, M. (2012). KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Research, 40(Database issue), D109–D114.
33. Kifle, L., Ortiz, D., & Shea, T. B. (2009). Deprivation of folate and B12 increases neurodegeneration beyond that accompanying deprivation of either vitamin alone. Journal of Alzheimer’s Disease, 16(3), 533–540.
34. Kronenberg, F., Trenkwalder, E., Kronenberg, M. F., Konig, P., Utermann, G., & Dieplinger, H. (1998). Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a). Kidney International, 54(4), 1385–1389.
35. Kutmon, M., et al. (2015). WikiPathways: Capturing the full diversity of pathway knowledge. Nucleic Acids Research. doi:10.1093/nar/gkv1024.
36. Lalic, N. M., et al. (2008). Glucose homeostasis in Huntington disease: Abnormalities in insulin sensitivity and early-phase insulin secretion. Archives of Neurology, 65(4), 476–480.
37. Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014). Voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biology, 15(2), R29.
38. Leclerc, D., et al. (1998). Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proceedings of the National Academy of Sciences of the United States of America, 95(6), 3059–3064.
39. Li, J., & Ji, L. (2005). Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb), 95(3), 221–227.
40. Mandaviya, P. R., Stolk, L., & Heil, S. G. (2014). Homocysteine and DNA methylation: A review of animal and human literature. Molecular Genetics and Metabolism, 113(4), 243–252.
41. Marcucci, H., Paoletti, L., Jackowski, S., & Banchio, C. (2010). Phosphatidylcholine biosynthesis during neuronal differentiation and its role in cell fate determination. Journal of Biological Chemistry, 285(33), 25382–25393.
42. Mastrokolias, A., den Dunnen, J. T., van Ommen, G. B., ‘t Hoen, P. A., & van Roon-Mom, W. M. (2012). Increased sensitivity of next generation sequencing-based expression profiling after globin reduction in human blood RNA. BMC Genomics, 13, 28.
43. Mastrokolias, A., et al. (2015). Huntington’s disease biomarker progression profile identified by transcriptome sequencing in peripheral blood. European Journal of Human Genetics, 23(10), 1349–1356.
44. Mihm, M. J., Amann, D. M., Schanbacher, B. L., Altschuld, R. A., Bauer, J. A., & Hoyt, K. R. (2007). Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease. Neurobiology of Disease, 25(2), 297–308.
45. Mitchell, E. S., Conus, N., & Kaput, J. (2014). B vitamin polymorphisms and behavior: Evidence of associations with neurodevelopment, depression, schizophrenia, bipolar disorder and cognitive decline. Neuroscience and Biobehavioral Reviews, 47, 307–320.
46. Mochel, F., Benaich, S., Rabier, D., & Durr, A. (2011). Validation of plasma branched chain amino acids as biomarkers in Huntington disease. Archives of Neurology, 68(2), 265–267.
47. Mochel, F., & Haller, R. G. (2011). Energy deficit in Huntington disease: Why it matters. The Journal of Clinical Investigation, 121(2), 493–499.
48. Mochel, F., et al. (2007). Early energy deficit in Huntington disease: Identification of a plasma biomarker traceable during disease progression. PLoS ONE, 2(7), e647.
49. Nishiumi, S., Suzuki, M., Kobayashi, T., Matsubara, A., Azuma, T., & Yoshida, M. (2014). Metabolomics for biomarker discovery in gastroenterological cancer. Metabolites, 4(3), 547–571.
50. Nyholt, D. R. (2004). A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. American Journal of Human Genetics, 74(4), 765–769.
51. Olthof, M. R., Brink, E. J., Katan, M. B., & Verhoef, P. (2005). Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men. American Journal of Clinical Nutrition, 82(1), 111–117.
52. Perdelli, F., Cristina, M. L., Sartini, M., & Orlando, P. (2002). Urinary hydroxyproline as a biomarker of effect after exposure to nitrogen dioxide. Toxicology Letters, 134(1–3), 319–323.
53. Petersen, A. K., et al. (2012). On the hypothesis-free testing of metabolite ratios in genome-wide and metabolome-wide association studies. BMC Bioinformatics, 13, 120.
54. Romero, P., Wagg, J., Green, M. L., Kaiser, D., Krummenacker, M., & Karp, P. D. (2005). Computational prediction of human metabolic pathways from the complete human genome. Genome Biology, 6(1), R2.
55. Romisch-Margl, W., Prehn, C., Bogumil, R., Rohring, C., Suhre, K., & Adamski, J. (2012). Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics. Metabolomics, 8(1), 133–142.
56. Rosenberg, G. S., & Davis, K. L. (1982). The use of cholinergic precursors in neuropsychiatric diseases. American Journal of Clinical Nutrition, 36(4), 709–720.
57. Ross, C. A., et al. (2014). Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol, 10(4), 204–216.
58. Runne, H., et al. (2008). Dysregulation of gene expression in primary neuron models of Huntington’s disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. Journal of Neuroscience, 28(39), 9723–9731.
59. Ryu, J. K., Kim, S. U., & McLarnon, J. G. (2003). Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington’s disease. Experimental Neurology, 183(2), 700–704.
60. Salvatore, E., et al. (2011). Growth hormone response to arginine test differentiates between two subgroups of Huntington’s disease patients. Journal of Neurology, Neurosurgery and Psychiatry, 82(5), 543–547.
61. Sassone, J., Colciago, C., Cislaghi, G., Silani, V., & Ciammola, A. (2009). Huntington’s disease: The current state of research with peripheral tissues. Experimental Neurology, 219(2), 385–397.
62. Schnackenberg, L. K., & Beger, R. D. (2007). Metabolomic biomarkers: Their role in the critical path. Drug Discovery Today: Technologies, 4(1), 13–16.
63. Sipione, S., et al. (2002). Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Human Molecular Genetics, 11(17), 1953–1965.
64. Slotte, J. P. (2013). Biological functions of sphingomyelins. Progress in Lipid Research, 52(4), 424–437.
65. Stanger, O., et al. (2009). Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: Review and treatment recommendations. Expert Review of Neurotherapeutics, 9(9), 1393–1412.
66. Stephenson, D. T., Lemere, C. A., Selkoe, D. J., & Clemens, J. A. (1996). Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer’s disease brain. Neurobiology of Disease, 3(1), 51–63.
67. Suhre, K., et al. (2010). Metabolic footprint of diabetes: A multiplatform metabolomics study in an epidemiological setting. PLoS ONE, 5(11), e13953.
68. Sun, G. Y., Xu, J., Jensen, M. D., & Simonyi, A. (2004). Phospholipase A2 in the central nervous system: Implications for neurodegenerative diseases. Journal of Lipid Research, 45(2), 205–213.
69. Tabrizi, S. J., et al. (2013). Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurology, 12(7), 637–649.
70. Takamura, A., et al. (2008). Enhanced autophagy and mitochondrial aberrations in murine G(M1)-gangliosidosis. Biochemical and Biophysical Research Communications, 367(3), 616–622.
71. Tang, C. C., et al. (2013). Metabolic network as a progression biomarker of premanifest Huntington’s disease. J Clin Invest, 123(9), 4076–4088.
72. The Huntington’s Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell, 72(6), 971–983.
73. Tsang, T. M., Haselden, J. N., & Holmes, E. (2009). Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington’s disease. Neurochemical Research, 34(7), 1261–1271.
74. Tsugawa, H., et al. (2015). MS-DIAL: Data-independent MS/MS deconvolution for comprehensive metabolome analysis. Nature Methods, 12(6), 523–526.
75. Underwood, B. R., et al. (2006). Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain, 129(Pt 4), 877–886.
76. Valenza, M., & Cattaneo, E. (2011). Emerging roles for cholesterol in Huntington’s disease. Trends in Neurosciences, 34(9), 474–486.
77. Valenza, M., et al. (2005). Dysfunction of the cholesterol biosynthetic pathway in Huntington’s disease. Journal of Neuroscience, 25(43), 9932–9939.
78. Vouk, K., Ribic-Pucelj, M., Adamski, J., & Rizner, T. L. (2016). Altered levels of acylcarnitines, phosphatidylcholines, and sphingomyelins in peritoneal fluid from ovarian endometriosis patients. Journal of Steroid Biochemistry and Molecular Biology, 159, 60–69.
79. Wang, X., Zhang, A., & Sun, H. (2013). Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology, 57(5), 2072–2077.
80. Wang, R., et al. (2014). Metabolic and hormonal signatures in pre-manifest and manifest Huntington’s disease patients. Frontiers in Physiology, 5, 231.
81. Wherrett, J. R., & Brown, B. L. (1969). Erythrocyte glycolipids in Huntington’s chorea. Neurology, 19(5), 489–493.
82. Wolthers, K. R., Lou, X., Toogood, H. S., Leys, D., & Scrutton, N. S. (2007). Mechanism of coenzyme binding to human methionine synthase reductase revealed through the crystal structure of the FNR-like module and isothermal titration calorimetry. Biochemistry, 46(42), 11833–11844.
83. Xia, J., Sinelnikov, I. V., Han, B., & Wishart, D. S. (2015). MetaboAnalyst 3.0—making metabolomics more meaningful. Nucleic Acids Research, 43(W1), W251–W257.
84. Yet, I., et al. (2016). Genetic influences on metabolite levels: A comparison across metabolomic platforms. PLoS ONE, 11(4), e0153672.
85. Yu, Z., et al. (2011). Differences between human plasma and serum metabolite profiles. PLoS ONE, 6(7), e21230.
86. Yu, D., et al. (2012). Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell, 150(5), 895–908.
87. Zielonka, D., Piotrowska, I., Marcinkowski, J. T., & Mielcarek, M. (2014). Skeletal muscle pathology in Huntington’s disease. Front Physiol, 5, 380.
88. Zilberter, Y., Gubkina, O., & Ivanov, A. I. (2015). A unique array of neuroprotective effects of pyruvate in neuropathology. Frontiers in Neuroscience, 9, 17.